Drug & intervention

dabrafenib

RxCUI 1424911

Clinical trials14
Recruiting2
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

14 shown
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.NCT07440290 · 2026-04-01
RECRUITING
Dabrafenib and/or Trametinib Rollover StudyNCT03340506 · 2018-01-26
RECRUITING
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung CancerNCT06532149 · 2024-08-05
UNKNOWN
A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLCNCT04452877 · 2020-08-19
COMPLETED
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway MutationsNCT04418167 · 2020-06-18
SUSPENDED
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialNCT03878524 · 2020-04-01
TERMINATED
Pediatric Long-Term Follow-up and Rollover StudyNCT03975829 · 2019-11-04
ACTIVE_NOT_RECRUITING
Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLCNCT02672358 · 2018-09-03
WITHDRAWN
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060 · 2015-08-17
ACTIVE_NOT_RECRUITING
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 MutationsNCT02124772 · 2015-01-15
COMPLETED
A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)NCT02130466 · 2014-05-29
COMPLETED
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib AloneNCT02027961 · 2013-12-20
COMPLETED
Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.NCT01336634 · 2011-08-05
COMPLETED
Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung CancerNCT04507919
NO_LONGER_AVAILABLE

Conditions being studied

Melanoma4Cancer3Glioma2Multiple Myeloma2Refractory Malignant Solid Neoplasm2Solid Tumors2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Advanced Lymphoma1Advanced Malignant Solid Neoplasm1Anaplastic Astrocytoma1Anaplastic Ganglioglioma1Anaplastic Oligodendroglioma1Anaplastic Pleomorphic Xanthoastrocytoma1Anatomic Stage IV Breast Cancer AJCC v81Anemia1Angiocentric Glioma1Ann Arbor Stage III Hodgkin Lymphoma1Ann Arbor Stage III Non-Hodgkin Lymphoma1Ann Arbor Stage IV Hodgkin Lymphoma1Ann Arbor Stage IV Non-Hodgkin Lymphoma1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.